fast track, Sanofi and COVID-19 testing

Sanofi’s combo vaccines gain FDA fast track designation
The candidates merge two existing vaccines that have demonstrated favourable tolerability through randomised controlled studies.
Monroe County's Sanofi plant fast-tracked for combination COVID/flu vaccine approval
The US Food and Drug Administration(FDA) has granted Fast Track designation to two non-mRNA combination vaccine candidates put forward by Sanofi.
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the USFirst non-mRNA combination
FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates
Sanofi SNY announced that the FDA has granted a Fast Track designation to two combination vaccine candidates to prevent influenza and COVID-19 infections in people aged 50 years and above. NCT06695117,
US FDA grants fast track designation to two Sanofi’s combination vaccine candidates to prevent influenza & Covid-19 infections
US FDA grants fast track designation to two Sanofi’s combination vaccine candidates to prevent influenza & Covid-19 infections: Paris Thursday, December 12, 2024, 10:00 Hrs [IST
Two Sanofi combination vaccine candidates for prevention of influenza, COVID gets USFDA Fast Track designation
Paris: The US Food and Drug Administration (USFDA) has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infections in individuals
Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
The US Food and Drug Administration has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infections in individuals 50 years of age and older.
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
FierceBiotech8d
Sanofi-backed Nuvig marches lead autoimmune therapy into phase 2 with $161M series B
Big Pharma-backed immunomodulation biotech Nuvig Therapeutics is moving its lead asset into phase 2 trials using a $161 ...
BioSpace8d
Nuvig Ropes in $161M Series B From Big Pharma Players for Autoimmune Indications
California-based biotech Nuvig Therapeutics scooped up $161 million from the investment arms of Sanofi, Bayer, Novo Holdings, ...
Medscape5d
Rilzabrutinib Shines in Phase 3 Trial of Tough-to-Treat Immune Thrombocytopenia
The oral BTK inhibitor rilzabrutinib led to rapid and durable platelet responses, reduced bleeding, and improved fatigue in ...